L G Manjil

Learn More
PK 11195 is a selective and specific ligand for the peripheral-type benzodiazepine binding site. Its potential for in vivo visualisation of lesioned human brain using positron emission tomography (PET) is currently being assessed. The present study examines the relationship between the temporal development of a local ischaemic lesion with its associated(More)
PK 11195 is a selective ligand for the peripheral-type benzodiazepine binding site (PTBBS). There are few such sites in normal brain but their number increases in association with tissue necrosis. The time-course of appearance of PTBBS around a focally induced ischaemic lesion in frontal cortex of rat brain was established by autoradiography using(More)
The peripheral-type benzodiazepine binding site (PTBBS) ligand, PK 11195, is known to be a marker of damage in the central nervous system, the binding being predominantly to macrophages. Using photochemically induced focal cortical ischaemia as a lesion model in the rat, we have investigated the detection of secondary lesions using [3H]PK 11195 and ex vivo(More)
Peripheral-type benzodiazepine binding sites are not normally present in most cerebral tissues, but following neuronal damage, the cells involved in the ensuing gliosis show a marked expression of these sites. In a unilateral excitotoxic striatal lesion in the rat, we sought to determine whether the isoquinoline derivatives PK11195 and PK14105 bind to these(More)
  • 1